Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7803709rdf:typepubmed:Citationlld:pubmed
pubmed-article:7803709lifeskim:mentionsumls-concept:C0002062lld:lifeskim
pubmed-article:7803709lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:7803709lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:7803709lifeskim:mentionsumls-concept:C1293122lld:lifeskim
pubmed-article:7803709lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7803709lifeskim:mentionsumls-concept:C1517564lld:lifeskim
pubmed-article:7803709pubmed:issue3lld:pubmed
pubmed-article:7803709pubmed:dateCreated1995-1-27lld:pubmed
pubmed-article:7803709pubmed:abstractTextWe have investigated the interaction between Cepharanthine (CEP), a multi-functional alkaloid that has the capacity to stabilize the cell membrane, and 5-fluorouracil (5-FU) against a human colon cancer cell line (RPMI 4788) transplanted into nude mice. Their anti-tumor effects were assessed in a group of 7 mice intravenously injected with CEP (5 mg/kg/day) and/or 5-FU (15 mg/kg/day) during a 3-week treatment. The results were compared with a control and a 5-FU group, which received saline solution and 5-FU alone, respectively. The tumors were harvested 2 h after 5-FU administration. On an additional 4 groups of 5 mice, the intratumoral concentration of 5-FU was assessed by a high performance liquid chromatographic (HPLC) method 2, 4, 6 and 12 h following CEP (5 mg/kg) injection 1 h prior to, simultaneously, and 1 h after injection of 5-FU (30 mg/kg). The mean (SD) intratumoral concentration of 5-FU was 0.16 (0.05) mu g/g, 0.32 (0.19) mu g/g, 0.32 (0.16) mu g/g and 0.21 (0.13) mu g/g in the control and the three other groups treated with CEP, respectively. This concentration was about twice as high in mice simultaneously treated with CEP compared to those treated by 5-FU alone. Relatively higher concentrations of 5-FU were noted up to 4 h following 5-FU injection in mice treated with CEP than in those injected only with 5-FU. CEP also enhanced the inhibitory effects of the 5-FU on tumor growth rate.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7803709pubmed:languageenglld:pubmed
pubmed-article:7803709pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:citationSubsetIMlld:pubmed
pubmed-article:7803709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7803709pubmed:statusMEDLINElld:pubmed
pubmed-article:7803709pubmed:issn0258-851Xlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:OnoMMlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:TanakaNNlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:KojimaKKlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:KataokaKKlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:OritaKKlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:MoreiraL FLFlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:MuroMMlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:NaomotoYYlld:pubmed
pubmed-article:7803709pubmed:authorpubmed-author:HorikiSSlld:pubmed
pubmed-article:7803709pubmed:issnTypePrintlld:pubmed
pubmed-article:7803709pubmed:volume8lld:pubmed
pubmed-article:7803709pubmed:ownerNLMlld:pubmed
pubmed-article:7803709pubmed:authorsCompleteYlld:pubmed
pubmed-article:7803709pubmed:pagination309-11lld:pubmed
pubmed-article:7803709pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:meshHeadingpubmed-meshheading:7803709-...lld:pubmed
pubmed-article:7803709pubmed:articleTitleIn vivo augmentation of the intratumoral concentration of 5-fluorouracil by cepharanthine--a biscoclaurine alkaloid.lld:pubmed
pubmed-article:7803709pubmed:affiliationFirst Department of Surgery, Okayama University Medical School, Japan.lld:pubmed
pubmed-article:7803709pubmed:publicationTypeJournal Articlelld:pubmed